admin – Page 4644 – Get News Story

Top Realtor Agent in Scottsdale, AZ, Introduces Cutting-Edge Real Estate Technologies for Enhanced Client Experience

SCOTTSDALE, AZ – Continuing their legacy of innovation, Those Callaways, established in 1996, are elevating the real estate experience in Scottsdale and beyond through the integration of cutting-edge technologies. This initiative, led by Joseph Callaway, is set to transform how properties are marketed and sold, bringing unmatched efficiency and reach to their clients.

“At Those Callaways, we’ve always prioritized our clients’ needs, and by embracing new technologies, we’re enhancing every aspect of the real estate transaction,” says Joseph Callaway, known by many as a top real estate agent in Scottsdale, AZ. From virtual home tours to advanced data analytics for pricing accuracy, the firm is focused on providing a seamless and sophisticated selling and buying process.

The technology also extends to communication and contract management, where Those Callaways utilize platforms that streamline these critical elements, making transactions smoother and faster. “Introducing these technologies not only improves our operations but also enriches the client experience,” explains Callaway. As a top Realtor in Scottsdale, AZ, Callaway ensures that his clients benefit from the best tools available in the industry.

Clients choosing Those Callaways for their real estate needs can expect a level of service that combines traditional client-care excellence with modern technological advances. This approach not only helps in selling homes with greater speed and efficiency but also in attracting buyers from across the globe. “Our goal is to make every transaction as effortless and effective as possible for our clients,” states Callaway.

Joseph Callaway encourages those interested in buying or selling to reach out early in their decision-making process. “Working with a real estate agent in Scottsdale, AZ, equipped with the best technology and expertise ensures that your real estate goals are met with the utmost precision and care.”

For more information or to experience the future of real estate today, visit https://www.thosecallaways.com/. Engage with a team that brings together decades of expertise and the most advanced real estate technologies to provide you with an exceptional service. Let the top Realtors in Scottsdale, AZ, help you navigate the market with ease and confidence.

Media Contact
Company Name: Those Callaways Real Estate
Contact Person: Joseph Callaway
Email: Send Email
Phone: +1 480 596 5751
Address:7217 E Shea Blvd.
City: Scottsdale
State: Arizona 85260
Country: United States
Website: https://www.thosecallaways.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor Agent in Scottsdale, AZ, Introduces Cutting-Edge Real Estate Technologies for Enhanced Client Experience

Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline

The Key Immune Thrombocytopenia Purpura Companies in the market include – Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others.

DelveInsight’s “Immune Thrombocytopenia Purpura Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Immune Thrombocytopenia Purpura, historical and forecasted epidemiology as well as the Immune Thrombocytopenia Purpura market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Immune Thrombocytopenia Purpura market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Immune Thrombocytopenia Purpura Market Forecast

Some of the key facts of the Immune Thrombocytopenia Purpura Market Report:

The Immune Thrombocytopenia Purpura market size was valued approximately USD 3,160 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In June 2024, Takeda (TSE:4502/NYSE:TAK) has shared positive findings from its Phase 2b randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and efficacy of mezagitamab (TAK-079) in treating persistent or chronic primary immune thrombocytopenia (ITP). ITP, a rare immune-mediated bleeding disorder, is marked by accelerated platelet destruction, leading to reduced platelet counts and increased bleeding risks. The results (Abstract #LB 01.1) were presented during the Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to launch a global Phase 3 trial for mezagitamab in ITP patients in the second half of FY2024.
In March 2024, Argenx announced that VYVGART (efgartigimod alfa) has been approved in Japan for the treatment of adults with Primary Immune Thrombocytopenia.
In 2023, the US held the largest market share for ITP in the 7MM, exceeding USD 1,870.
In the 7MM, the US had the highest number of prevalent ITP cases, with approximately 66,500 cases in 2023. This number is anticipated to rise throughout the forecast period.
The prevalence of the condition is significantly higher among adults compared to children.
In 2023, the US had approximately 20,600 diagnosed prevalent cases among males and around 35,000 cases among females.
Key Immune Thrombocytopenia Purpura Companies: Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others
Key Immune Thrombocytopenia Purpura Therapies: BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others
The Immune Thrombocytopenia Purpura epidemiology based on gender analyzed that the majority of cases of ITP are found in females as compared to the male population.
The Immune Thrombocytopenia Purpura market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Immune Thrombocytopenia Purpura pipeline products will significantly revolutionize the Immune Thrombocytopenia Purpura market dynamics.

Immune Thrombocytopenia Purpura Overview

Immune Thrombocytopenia Purpura (ITP) is a rare autoimmune disorder where the immune system mistakenly attacks and destroys platelets, which are essential for blood clotting. This leads to low platelet counts, causing symptoms such as easy bruising, prolonged bleeding, petechiae (small red or purple spots on the skin), and in severe cases, internal bleeding. ITP can be either acute, often affecting children, or chronic, more common in adults. Treatment typically focuses on managing symptoms and may include corticosteroids, immunoglobulin therapy, or in some cases, splenectomy.

Get a Free sample for the Immune Thrombocytopenia Purpura Market Report:

https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Immune Thrombocytopenia Purpura Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Immune Thrombocytopenia Purpura Epidemiology Segmentation:

The Immune Thrombocytopenia Purpura market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Immune Thrombocytopenia Purpura
Prevalent Cases of Immune Thrombocytopenia Purpura by severity
Gender-specific Prevalence of Immune Thrombocytopenia Purpura
Diagnosed Cases of Episodic and Chronic Immune Thrombocytopenia Purpura

Download the report to understand which factors are driving Immune Thrombocytopenia Purpura epidemiology trends @ Immune Thrombocytopenia Purpura Epidemiology Forecast

Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Immune Thrombocytopenia Purpura market or expected to get launched during the study period. The analysis covers Immune Thrombocytopenia Purpura market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Immune Thrombocytopenia Purpura Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Immune Thrombocytopenia Purpura Therapies and Key Companies

BT-595 (IgG Next Generation): Biotest
Efgartigimod (ARGX-113): Argenx
Rilzabrutinib(PRN-1008): Sanofi/ Principia Biopharma
Fostamatinib disodium: Rigel Pharmaceuticals
PRN1008: Principia Biopharma
LGD-4665: GlaxoSmithKline
Octagam 10%: Octapharma
Sym001: Symphogen A/S
R788: Kissei Pharma
BMS-986004: BMS-986004
Eltrombopag: GlaxoSmithKline
Romiplostim: Amgen
Hetrombopag Olamine: Jiangsu HengRui Medicine
Rituxan, Cyclophosphamide, Vincristine, Prednisone: Genentech, Inc.
Methylprednisolone and IVIG: Bayer
rituximab [MabThera/Rituxan]: Hoffmann-La Roche
PG2: PhytoHealth Corporation

Discover more about therapies set to grab major Immune Thrombocytopenia Purpura market share @ Immune Thrombocytopenia Purpura Treatment Market

Immune Thrombocytopenia Purpura Market Strengths

The increasing number of product launches, coupled with advancements in betterment of existing products will fuel the growth.
Higher adaptation and cost-effectiveness of corticosteroid drugs segment will hold the significant share in developed countries
Increased acceptance of TPO-RA as a second line of treatment will boost the growth.
Rising prevalence of the ITP worldwide and increasing awareness of the disease in the 7MM will drive the market growth during the forecast period.

Immune Thrombocytopenia Purpura Market Opportunities

The pipeline of Immune Thrombocytopenia is robust with the involvement of major players, such as BMS, Amgen, Protalex, Squibb,and others.

Scope of the Immune Thrombocytopenia Purpura Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Immune Thrombocytopenia Purpura Companies: Biotest, Argenx, Sanofi/ Principia Biopharma, Rigel Pharmaceuticals, Principia Biopharma, GlaxoSmithKline, Octapharma, Symphogen A/S, Kissei Pharma, Amgen, Jiangsu HengRui Medicine, Genentech, Inc., Bayer, Hoffmann-La Roche, Novartis, PhytoHealth Corporation, and others
Key Immune Thrombocytopenia Purpura Therapies: BT-595 (IgG Next Generation), Efgartigimod (ARGX-113), Rilzabrutinib(PRN-1008), Fostamatinib disodium, PRN1008, LGD-4665, Octagam 10%, Sym001, R788, Eltrombopag, Romiplostim, Hetrombopag Olamine, Rituxan, Cyclophosphamide, Vincristine, Prednisone, Methylprednisolone and IVIG, rituximab [MabThera/Rituxan], PG2, and others
Immune Thrombocytopenia Purpura Therapeutic Assessment: Immune Thrombocytopenia Purpura current marketed and Immune Thrombocytopenia Purpura emerging therapies
Immune Thrombocytopenia Purpura Market Dynamics: Immune Thrombocytopenia Purpura market drivers and Immune Thrombocytopenia Purpura market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Immune Thrombocytopenia Purpura Unmet Needs, KOL’s views, Analyst’s views, Immune Thrombocytopenia Purpura Market Access and Reimbursement

To know more about Immune Thrombocytopenia Purpura companies working in the treatment market, visit @ Immune Thrombocytopenia Purpura Clinical Trials and Therapeutic Assessment

Table of Contents

1. Immune Thrombocytopenia Purpura Market Report Introduction

2. Executive Summary for Immune Thrombocytopenia Purpura

3. SWOT analysis of Immune Thrombocytopenia Purpura

4. Immune Thrombocytopenia Purpura Patient Share (%) Overview at a Glance

5. Immune Thrombocytopenia Purpura Market Overview at a Glance

6. Immune Thrombocytopenia Purpura Disease Background and Overview

7. Immune Thrombocytopenia Purpura Epidemiology and Patient Population

8. Country-Specific Patient Population of Immune Thrombocytopenia Purpura

9. Immune Thrombocytopenia Purpura Current Treatment and Medical Practices

10. Immune Thrombocytopenia Purpura Unmet Needs

11. Immune Thrombocytopenia Purpura Emerging Therapies

12. Immune Thrombocytopenia Purpura Market Outlook

13. Country-Wise Immune Thrombocytopenia Purpura Market Analysis (2020–2034)

14. Immune Thrombocytopenia Purpura Market Access and Reimbursement of Therapies

15. Immune Thrombocytopenia Purpura Market Drivers

16. Immune Thrombocytopenia Purpura Market Barriers

17. Immune Thrombocytopenia Purpura Appendix

18. Immune Thrombocytopenia Purpura Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Immune Thrombocytopenia Purpura Market to Expand Significantly by 2034, States DelveInsight Report | Biotest, Argenx, Sanofi, Principia Biopharma, Rigel Pharma, Principia Biopharma, GlaxoSmithKline

Hypoxic Ischemic Encephalopathy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., J&J

The Key Hypoxic Ischemic Encephalopathy Companiesin the market include – Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., Johnson & Johnson, Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Allergan, Merz Pharma, , Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AbbVie Inc., Lily., VTV Therapeutics, H. Lundbeck A/S, ReAlta Life Sciences, Hope Biosciences, TauRx Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, and others.

DelveInsight’s “Hypoxic Ischemic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypoxic Ischemic Encephalopathy, historical and forecasted epidemiology as well as the Hypoxic Ischemic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hypoxic Ischemic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoxic Ischemic Encephalopathy Market Forecast

Some of the key facts of the Hypoxic Ischemic Encephalopathy Market Report:

The Hypoxic Ischemic Encephalopathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
According to the World Health Organization (WHO), hypoxic-ischemic encephalopathy ranks as the fifth leading cause of death among children under the age of five globally.
According to our estimates, neonatal hypoxic-ischemic encephalopathy is anticipated to occur in approximately 1.5 out of every 1,000 live births.
According to the Hypoxic-Ischemic Encephalopathy Help Center, around 10-20% of infants with moderate hypoxic-ischemic encephalopathy experience minor neurological conditions, while approximately 30-50% face more severe complications.
Key Hypoxic Ischemic Encephalopathy Companies: Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., Johnson & Johnson, Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Allergan, Merz Pharma, , Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AbbVie Inc., Lily., VTV Therapeutics, H. Lundbeck A/S, ReAlta Life Sciences, Hope Biosciences, GW Pharmaceuticals, TauRx Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, and others
Key Hypoxic Ischemic Encephalopathy Therapies: Sovateltide, TEMCELL (JR-031HIE), RLS-0071, HB-adMSCs, Additional cannabinoids, and others
The Hypoxic Ischemic Encephalopathy epidemiology based on gender analyzed that male infants are more vulnerable to neonatal Hypoxic Ischemic Encephalopathy and suffer more long-term deficits than female
The Hypoxic Ischemic Encephalopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoxic Ischemic Encephalopathy pipeline products will significantly revolutionize the Hypoxic Ischemic Encephalopathy market dynamics.

Hypoxic Ischemic Encephalopathy Overview

Hypoxic-ischemic encephalopathy (HIE) is a serious and life-threatening type of newborn brain damage (brain dysfunction) that occurs when the brain doesn’t receive enough oxygen and blood flow for a period of time. As the name suggests, Hypoxic means, not enough oxygen; ischemic means not enough blood flow; and encephalopathy means brain disorder.

Get a Free sample for the Hypoxic Ischemic Encephalopathy Market Report –

https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market

Hypoxic Ischemic Encephalopathy Epidemiology

Hypoxic Ischemic Encephalopathy Epidemiology Segmentation:

The Hypoxic Ischemic Encephalopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Hypoxic Ischemic Encephalopathy
Prevalent Cases of Hypoxic Ischemic Encephalopathy by severity
Gender-specific Prevalence of Hypoxic Ischemic Encephalopathy
Diagnosed Cases of Episodic and Chronic Hypoxic Ischemic Encephalopathy

Download the report to understand which factors are driving Hypoxic Ischemic Encephalopathy epidemiology trends @ Hypoxic Ischemic Encephalopathy Epidemiology Forecast

Hypoxic Ischemic Encephalopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoxic Ischemic Encephalopathy market or expected to get launched during the study period. The analysis covers Hypoxic Ischemic Encephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Hypoxic Ischemic Encephalopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypoxic Ischemic Encephalopathy Therapies and Key Companies

Sovateltide: Pharmazz
TEMCELL (JR-031HIE): JCR Pharma
RLS-0071: ReAlta Life Sciences
HB-adMSCs: Hope Biosciences
Additional cannabinoids: GW Pharmaceuticals

Discover more about therapies set to grab major Hypoxic Ischemic Encephalopathy market share @ Hypoxic Ischemic Encephalopathy Treatment Market

Hypoxic Ischemic Encephalopathy Market Strengths

This condition has high unmet needs in regards to the available therapy option. This creates a spaces for the pharmaceutical companies to launch their products with exclusivity and premium pricing

Hypoxic Ischemic Encephalopathy Market Opportunities

With the increasing global population, the incidence of Hypoxic ischemic encephalopathy has also surged, leading to increased opportunities for research and development

Scope of the Hypoxic Ischemic Encephalopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hypoxic Ischemic Encephalopathy Companies: Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., Johnson & Johnson, Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Allergan, Merz Pharma, , Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, AbbVie Inc., Lily., VTV Therapeutics, H. Lundbeck A/S, ReAlta Life Sciences, Hope Biosciences, GW Pharmaceuticals, TauRx Pharmaceuticals Ltd, DAIICHI SANKYO COMPANY, LIMITED, and others
Key Hypoxic Ischemic Encephalopathy Therapies: Sovateltide, TEMCELL (JR-031HIE), RLS-0071, HB-adMSCs, Additional cannabinoids, and others
Hypoxic Ischemic Encephalopathy Therapeutic Assessment: Hypoxic Ischemic Encephalopathy current marketed and Hypoxic Ischemic Encephalopathy emerging therapies
Hypoxic Ischemic Encephalopathy Market Dynamics: Hypoxic Ischemic Encephalopathy market drivers and Hypoxic Ischemic Encephalopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hypoxic Ischemic Encephalopathy Unmet Needs, KOL’s views, Analyst’s views, Hypoxic Ischemic Encephalopathy Market Access and Reimbursement

To know more about Hypoxic Ischemic Encephalopathy companies working in the treatment market, visit @ Hypoxic Ischemic Encephalopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hypoxic Ischemic Encephalopathy Market Report Introduction

2. Executive Summary for Hypoxic Ischemic Encephalopathy

3. SWOT analysis of Hypoxic Ischemic Encephalopathy

4. Hypoxic Ischemic Encephalopathy Patient Share (%) Overview at a Glance

5. Hypoxic Ischemic Encephalopathy Market Overview at a Glance

6. Hypoxic Ischemic Encephalopathy Disease Background and Overview

7. Hypoxic Ischemic Encephalopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypoxic Ischemic Encephalopathy

9. Hypoxic Ischemic Encephalopathy Current Treatment and Medical Practices

10. Hypoxic Ischemic Encephalopathy Unmet Needs

11. Hypoxic Ischemic Encephalopathy Emerging Therapies

12. Hypoxic Ischemic Encephalopathy Market Outlook

13. Country-Wise Hypoxic Ischemic Encephalopathy Market Analysis (2020–2034)

14. Hypoxic Ischemic Encephalopathy Market Access and Reimbursement of Therapies

15. Hypoxic Ischemic Encephalopathy Market Drivers

16. Hypoxic Ischemic Encephalopathy Market Barriers

17. Hypoxic Ischemic Encephalopathy Appendix

18. Hypoxic Ischemic Encephalopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypoxic Ischemic Encephalopathy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Takeda Pharma, Bayer AG, Novartis AG, Biogen, AstraZeneca, Eisai Co. Ltd., J&J

Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion

The Key Hypophosphatasia Companies in the market include – PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others.

DelveInsight’s “Hypophosphatasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypophosphatasia, historical and forecasted epidemiology as well as the Hypophosphatasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hypophosphatasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypophosphatasia Market Forecast

Some of the key facts of the Hypophosphatasia Market Report:

The Hypophosphatasia market size was valued at ~USD 880 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
The pipeline for Hypophosphatasia is not very robust, consisting of REC-01, ALXN1850, and others which are expected to launch during the forecast period [2022-2032]
According to DelveInsight’s analysis, the diagnosed prevalent cases of Hypophosphatasia in the 7MM were estimated to be around 6,500 in 2023. This number is expected to rise by 2034 due to increased disease awareness among healthcare professionals and the general public worldwide.
In 2023, the US reported the highest diagnosed prevalence of hypophosphatasia among the 7MM, with approximately 6,000 cases. These numbers are expected to grow from 2024 to 2034, largely due to advancements in genetic testing that have enabled expanded newborn screening programs across the country.
Among the EU4 countries and the UK, Germany reported the highest number of diagnosed hypophosphatasia cases, with about 84 cases, followed by France with 69 cases, and the UK with 68 cases. These numbers are expected to increase by 2034, driven by a heightened focus on research and clinical trials for the disease.
In the UK, mild hypophosphatasia cases accounted for nearly 82%, moderate cases for 16%, and severe cases for 2% in 2023. The number of cases for each severity level is expected to rise by 2034.
Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others
Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others
The Hypophosphatasia epidemiology based on severity-specific cases analyzed that mild Hypophosphatasia was most prevalent in the US, followed by moderate and severe Hypophosphatasia
The Hypophosphatasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypophosphatasia pipeline products will significantly revolutionize the Hypophosphatasia market dynamics.

Hypophosphatasia Overview

Hypophosphatasia is defined as a rare, genetic metabolic disorder characterized by impaired mineralization of bones and teeth, according to National Organization for Rare Disorders (NORD). Defective mineralization results in bones that are soft and prone to fracture and deformity and it also leads to tooth loss. Depending on the specific form, it can be inherited in an autosomal recessive or dominant manner.

Get a Free sample for the Hypophosphatasia Market Report

https://www.delveinsight.com/sample-request/hypophosphatasia-market

Hypophosphatasia Epidemiology

Hypophosphatasia Epidemiology Segmentation:

The Hypophosphatasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Hypophosphatasia
Prevalent Cases of Hypophosphatasia by severity
Gender-specific Prevalence of Hypophosphatasia
Diagnosed Cases of Episodic and Chronic Hypophosphatasia

Download the report to understand which factors are driving Hypophosphatasia epidemiology trends @ Hypophosphatasia Epidemiology Forecast

Hypophosphatasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypophosphatasia market or expected to get launched during the study period. The analysis covers Hypophosphatasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Hypophosphatasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypophosphatasia Therapies and Key Companies

REC-01: PuREC
ALXN1850: AstraZeneca
BPS804: Ultragenyx Pharmaceutical Inc

Discover more about therapies set to grab major Hypophosphatasia market share @ Hypophosphatasia Treatment Market

Hypophosphatasia Market Strengths

Advancements in understanding the pathophysiology and genetics of Hypophosphatasia, thereby elucidating new targets for treatment
The approval of ERT by various regulatory authorities is a game changer, improving clinical manifestations, survival, and QoL

Hypophosphatasia Market Barriers

Developing specific biochemical biomarker-based assays with an increased understanding of differential diagnosis among physicians will lead to improvements in diagnosis, thus opening the windows of opportunity for new treatment options
There is a need for pharmacotherapeutic interventions for milder adult-onset of disease, which has little mortality and a high disease burden

Scope of the Hypophosphatasia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others
Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others
Hypophosphatasia Therapeutic Assessment: Hypophosphatasia current marketed and Hypophosphatasia emerging therapies
Hypophosphatasia Market Dynamics: Hypophosphatasia market drivers and Hypophosphatasia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hypophosphatasia Unmet Needs, KOL’s views, Analyst’s views, Hypophosphatasia Market Access and Reimbursement

To know more about Hypophosphatasia companies working in the treatment market, visit @ Hypophosphatasia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hypophosphatasia Market Report Introduction

2. Executive Summary for Hypophosphatasia

3. SWOT analysis of Hypophosphatasia

4. Hypophosphatasia Patient Share (%) Overview at a Glance

5. Hypophosphatasia Market Overview at a Glance

6. Hypophosphatasia Disease Background and Overview

7. Hypophosphatasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypophosphatasia

9. Hypophosphatasia Current Treatment and Medical Practices

10. Hypophosphatasia Unmet Needs

11. Hypophosphatasia Emerging Therapies

12. Hypophosphatasia Market Outlook

13. Country-Wise Hypophosphatasia Market Analysis (2020–2034)

14. Hypophosphatasia Market Access and Reimbursement of Therapies

15. Hypophosphatasia Market Drivers

16. Hypophosphatasia Market Barriers

17. Hypophosphatasia Appendix

18. Hypophosphatasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion

Old Skool Queene Celebrates Friendship with New Afrobeat Single “Madanfo”

Immerse yourself in the rhythms of Ghana and discover the heartfelt journey behind “Madanfo.” Available for pre-order now!

Embark on a musical voyage with Old Skool Queene, a Washington, DC native whose artistic journey has led her to Ghana, inspiring the latest single, “Madanfo.” With its infectious Afrobeat rhythms, “Madanfo” celebrates friendship and the warm, inviting nature of the Ghanaian people who embraced Queene during her travels. Written in 2023 during her stay in Ghana, the song encapsulates her experiences and honors the spirit of camaraderie and warmth she encountered.

While Queene was working on completing her album “ThisIs4U-2 Get Your Roll On,” a serendipitous meeting with a Ghanaian singer at a local studio added another dimension to her music. This collaboration flourished into “Madanfo,” a track enriched with authentic Ghanaian flair, accentuated by the melodic contributions from her Ghanaian counterpart. The song’s remix, recorded later, draws attention to the importance of the lyrics and the universal value of friendship, spreading a message of love and unity across cultures.

Fans can now pre-order “Madanfo” on Old Skool Queene’s website before its Apple release on December 19, 2023. An immersive listening experience awaits those eager to explore the fusion of world sounds with a personal narrative of connection and joy.

Join the global Tik Tok lyric challenge and show off your creativity as part of Old Skool Queene’s vibrant community. Download your favorite tracks and add them to your playlist today for a unique musical experience.

ABOUT

Old Skool Queene is a singer-songwriter, poet, and podcaster from Washington, DC, renowned for her unique blend of R&B, poetry, and a passion for roller skating. After years of cultivating her talents and musical interests, she continues to channel her experiences from vibrant cultural interactions into compelling music. During her numerous travels to Africa, particularly Ghana, she has built strong friendships and embraced opportunities to support local communities. As an advocate for roller skating, Queene invites enthusiasts to join her in Accra for the First Ghana On Wheels Tour in April 2025, merging sports, culture, and music.

LINKS

https://oldskoolqueene.net/music-catalog#my-music

https://youtu.be/L0CFMf8RNTg?si=9a8lBpCZAGiWbJAR

https://music.apple.com/us/artist/old-skool-queene/1266833809 https://ffm.to/exapd2v

https://gofund.me/f18a493d

https://podcasts.apple.com/us/podcast/oldskoolqueenes-podcast/id1542433592

https://oldskoolqueene.net/

https://www.instagram.com/oldskoolqueeneafrica/?igsh=MW1rcm0zZTlma3B6Zw%3D%3D&utm_source=qr

https://x.com/oldskoolqueene

https://www.youtube.com/@Oldskoolqueene2000/videos

@oldskoolqueene2

Media Contact
Company Name: OLD SKOOL QUEENE
Email: Send Email
Phone: 800-983-1362
City: Camp Springs
State: Maryland
Country: United States
Website: https://oldskoolqueene.net/music-catalog#my-music

Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma

The Key Hypertrophic Cardiomyopathy Companies in the market include – Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others.

DelveInsight’s “Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hypertrophic Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertrophic Cardiomyopathy Market Forecast

Some of the key facts of the Hypertrophic Cardiomyopathy Market Report:

The Hypertrophic Cardiomyopathy market size was valued ~USD 646 million in 2023 and is anticipated to grow with a significant CAGR of 20% during the study period (2020-2034)
In September 2024, Edgewise Therapeutics reported promising top-line results from two clinical trials evaluating EDG-7500 as a potential treatment for obstructive hypertrophic cardiomyopathy (HCM). The findings include data from a Phase I trial in healthy participants and the single-dose arm of the Phase II CIRRUS-HCM trial. EDG-7500, an oral and selective modulator, is specifically designed to target cardiac relaxation challenges associated with HCM.
In April 2024, Imbria Pharmaceuticals, Inc., a clinical-stage cardiometabolic company focused on developing innovative therapies to enhance patient symptoms and functional capacity by improving cellular energetics, announced that findings from the Phase 2 IMPROVE-HCM clinical trial investigating ninerafaxstat in patients with symptomatic nHCM were unveiled during a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).
In 2023, the United States held the largest market share for Hypertrophic Cardiomyopathy, representing about 78% of the total market size across the 7MM, surpassing other key markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
In 2023, Germany had the largest Hypertrophic Cardiomyopathy market size among European countries, reaching approximately USD 33 million, whereas Spain had the smallest market size, around USD 23 million.
In 2023, the market size for Hypertrophic Cardiomyopathy in Japan was approximately USD 5 million, representing 1% of the total 7MM market.
According to DelveInsight’s analysis, the estimated total number of prevalent cases of Hypertrophic Cardiomyopathy in the 7MM was approximately 1,079,000 in 2023.
In 2023, the United States had the highest number of diagnosed prevalent cases of Hypertrophic Cardiomyopathy, estimated at around 118,000, with expectations of growth in the future.
In 2023, Germany had the highest number of diagnosed prevalent cases of Hypertrophic Cardiomyopathy among European countries, with approximately 32,000 cases, followed by France with around 25,000. Spain had the lowest diagnosed prevalence, with about 19,000 cases.
In 2023, Japan had around 4,000 diagnosed prevalent cases of Hypertrophic Cardiomyopathy, representing approximately 2% of the total cases across the 7MM.
In 2023, the United States saw a higher prevalence of diagnosed Hypertrophic Cardiomyopathy cases in males (~57%) compared to females (~43%), which can be attributed to factors like hormonal differences, physiological variations, lifestyle, and occupational influences.
In the UK, in 2023, Obstructive hypertrophic cardiomyopathy had the highest number of cases, with approximately 16,000, while Non-obstructive hypertrophic cardiomyopathy had the fewest, with around 8,000 cases.
Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
The Hypertrophic Cardiomyopathy epidemiology based on gender analyzed males are more affected by Hypertrophic Cardiomyopathy than females.
The Hypertrophic Cardiomyopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypertrophic Cardiomyopathy pipeline products will significantly revolutionize the Hypertrophic Cardiomyopathy market dynamics.

Hypertrophic Cardiomyopathy Overview

Hypertrophic Cardiomyopathy (HCM) is a condition in which the heart muscle becomes abnormally thick (hypertrophied). This thickening can make it harder for the heart to pump blood effectively and can lead to various complications. HCM is often inherited and can affect people of all ages.

Get a Free sample for the Hypertrophic Cardiomyopathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market

Hypertrophic Cardiomyopathy Epidemiology

Hypertrophic Cardiomyopathy Epidemiology Segmentation:

The Hypertrophic Cardiomyopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Hypertrophic Cardiomyopathy
Prevalent Cases of Hypertrophic Cardiomyopathy by severity
Gender-specific Prevalence of Hypertrophic Cardiomyopathy
Diagnosed Cases of Episodic and Chronic Hypertrophic Cardiomyopathy

Download the report to understand which factors are driving Hypertrophic Cardiomyopathy epidemiology trends @ Hypertrophic Cardiomyopathy Epidemiology Forecast

Hypertrophic Cardiomyopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypertrophic Cardiomyopathy market or expected to get launched during the study period. The analysis covers Hypertrophic Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Hypertrophic Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypertrophic Cardiomyopathy Therapies and Key Companies

EDG-7500: Edgewise Therapeutics, Inc.
Sotagliflozin: Lexicon Pharmaceuticals
HRS-1893: Shandong Suncadia Medicine
Aficamten: Ji Xing Pharmaceuticals
RP-A501: Rocket Pharmaceuticals
Mavacamten: Bristol-Myers Squibb
MYK-224: Bristol-Myers Squibb
LCZ696: Novartis
Ranolazine: Gilead Sciences
CK-3773274: Cytokinetics
IMB-1018972: Imbria Pharmaceuticals
MYK-461: MyoKardia, Inc.
Aficamten: Cytokinetics
TN-201: Tenaya Therapeutics
LCZ696: Novartis

Discover more about therapies set to grab major Hypertrophic Cardiomyopathy market share @ Hypertrophic Cardiomyopathy Treatment Landscape

Hypertrophic Cardiomyopathy Market Drivers

Genetic diagnosis
Robust Hypertrophic Cardiomyopathy pipeline
Evolution of surgical techniques
Increasing number of cases

Hypertrophic Cardiomyopathy Market Barriers

Under diagnosis
Missing causal genes
Knowledge gaps

Scope of the Hypertrophic Cardiomyopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
Hypertrophic Cardiomyopathy Therapeutic Assessment: Hypertrophic Cardiomyopathy current marketed and Hypertrophic Cardiomyopathy emerging therapies
Hypertrophic Cardiomyopathy Market Dynamics: Hypertrophic Cardiomyopathy market drivers and Hypertrophic Cardiomyopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hypertrophic Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Hypertrophic Cardiomyopathy Market Access and Reimbursement

To know more about Hypertrophic Cardiomyopathy companies working in the treatment market, visit @ Hypertrophic Cardiomyopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hypertrophic Cardiomyopathy Market Report Introduction

2. Executive Summary for Hypertrophic Cardiomyopathy

3. SWOT analysis of Hypertrophic Cardiomyopathy

4. Hypertrophic Cardiomyopathy Patient Share (%) Overview at a Glance

5. Hypertrophic Cardiomyopathy Market Overview at a Glance

6. Hypertrophic Cardiomyopathy Disease Background and Overview

7. Hypertrophic Cardiomyopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypertrophic Cardiomyopathy

9. Hypertrophic Cardiomyopathy Current Treatment and Medical Practices

10. Hypertrophic Cardiomyopathy Unmet Needs

11. Hypertrophic Cardiomyopathy Emerging Therapies

12. Hypertrophic Cardiomyopathy Market Outlook

13. Country-Wise Hypertrophic Cardiomyopathy Market Analysis (2020–2034)

14. Hypertrophic Cardiomyopathy Market Access and Reimbursement of Therapies

15. Hypertrophic Cardiomyopathy Market Drivers

16. Hypertrophic Cardiomyopathy Market Barriers

17. Hypertrophic Cardiomyopathy Appendix

18. Hypertrophic Cardiomyopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma

A Better Solution In Home Care Wichita Continues Commitment to Improving Seniors’ Lives with Compassionate Elderly Home Care in Derby, KS

The company reinforces its dedication to quality in-home care in Derby, KS.

Derby, KS – A Better Solution In Home Care Wichita, a leading provider of elderly home care services, proudly reaffirms its ongoing commitment to enhancing the lives of seniors in Derby, KS. By providing compassionate and individualized support, the company aims to help seniors live independently and comfortably in their own homes. This announcement underscores A Better Solution’s dedication to meeting the unique needs of elderly residents by offering essential in-home assistance for daily living and health needs.

“At A Better Solution In Home Care Wichita, we believe that every senior deserves quality care that respects their independence and dignity,” said Gustavo Torres, Owner of A Better Solution In Home Care Wichita. “Our mission is to support families in Derby, KS, by offering home care services that make a positive impact on the lives of our elderly clients. We’re here to provide not just care but peace of mind for families who entrust us with their loved ones’ well-being.”

With a focus on elderly home care, A Better Solution offers a range of services from assistance with personal care and medication management to companionship and household support. This compassionate approach is tailored to ensure each senior receives care that aligns with their specific needs, helping them stay active and engaged in the comfort of their home. As the aging population grows, demand for quality elderly home care in Derby, KS, continues to rise, and A Better Solution remains committed to addressing these needs with the highest standards of service.

Home care offers numerous benefits to seniors by helping them maintain independence in a familiar setting while receiving the support they need for a comfortable and safe lifestyle. By opting for in-home care, families can ensure their elderly loved ones enjoy the benefits of one-on-one care and personalized attention, which is often lacking in institutional care settings. This type of care is tailored to each senior’s unique physical, emotional, and social needs, promoting both independence and dignity.

In addition to personalized attention, in-home care provides an invaluable level of flexibility for families, allowing them to schedule services that fit their lifestyle and the needs of their loved ones. Home care services include assistance with daily activities like bathing, grooming, medication management, and even companionship, reducing the risk of isolation and depression among seniors. With skilled caregivers available, seniors receive the help they need to manage day-to-day tasks, promoting an enhanced quality of life without the need for relocation.

Home care services are also cost-effective, often making it a more accessible choice for families than traditional residential care facilities. Families who choose home care for their elderly loved ones not only gain peace of mind but also provide their loved ones with a stable, loving environment where they feel safe and valued. A Better Solution In Home Care Wichita remains dedicated to supporting seniors and their families by providing high-quality, affordable care services that align with their values and priorities.

Families seeking reliable and compassionate elderly home care in Derby, KS, can learn more about A Better Solution’s services by visiting their website at https://abshomecarewichita.com

About A Better Solution In-Home Care:

A Better Solution In Home Care Wichita is a premier provider of elderly home care in Derby, KS, dedicated to helping seniors live with dignity and independence. The company’s experienced and caring professionals offer personalized in-home care solutions, making it a trusted partner for families seeking compassionate support for their loved ones. A Better Solution remains steadfast in its mission to deliver the best care possible to seniors throughout the Derby community.

Media Contact
Company Name: A Better Solution In Home Care
Contact Person: Gustavo Torres
Email: Send Email
Phone: +1 316 295 3282
Address:815 N Waco Ave Suite 20
City: Wichita
State: KS
Country: United States
Website: https://abshomecarewichita.com/

Alliance Senior Care Reinforces Commitment to Compassionate In-Home Care in Bloomfield Hills, MI

Meeting the growing demand for personalized home care in Bloomfield Hills, MI, Alliance Senior Care offers dependable, compassionate support for families and seniors.

Bloomfield Hills, MI – Alliance Senior Care is proud to reaffirm its dedication to providing compassionate and reliable in-home care in Bloomfield Hills, MI. In response to the community’s need for trustworthy home care solutions, Alliance Senior Care focuses on helping families and their loved ones receive the quality care they deserve from home comfort. As part of this commitment, Alliance Senior Care prioritizes a personalized approach, ensuring each client receives unique and dignified support tailored to their needs.

“At Alliance Senior Care, we believe that every individual deserves quality care that respects their independence while ensuring their safety and well-being,” said Dina Hurnevich, representative of Alliance Senior Care. “Our compassionate approach to home care in Bloomfield Hills, MI is designed to give families peace of mind, knowing their loved ones are well-cared for by trained professionals who genuinely care about their quality of life.”

Alliance Senior Care’s comprehensive services cover a range of needs, from essential daily assistance and companionship to specialized care for those managing chronic health conditions. By providing in-home care, the team at Alliance Senior Care strives to foster independence and comfort, promoting the well-being of seniors who wish to age in place. Their caregivers have the experience and compassion to support clients with dignity and respect, offering relief to families throughout Bloomfield Hills, MI.

For seniors, aging at home offers comfort and a significant boost to their mental and emotional well-being. Familiar surroundings help maintain a sense of independence, which is essential for mental health. Home care provides the necessary support for daily activities, allowing seniors to retain control over their routines and live with dignity. Studies show that seniors who age in place tend to experience greater satisfaction and reduced levels of depression, highlighting the importance of accessible, in-home care options.

Furthermore, in-home care is vital in reducing hospital readmissions and emergency room visits among seniors. Alliance Senior Care’s caregivers are trained to monitor and manage health conditions, provide medication reminders, and assist with mobility, all of which contribute to physical health and safety at home. This proactive approach helps minimize the risks associated with falls, mismanaged medications, and other health complications, offering families peace of mind that their loved ones are receiving attentive, consistent care.

Families and individuals interested in learning more about in-home care in Bloomfield Hills, MI and the range of services provided by Alliance Senior Care can visit their website for further details. For compassionate, professional home care services tailored to each unique individual, Alliance Senior Care is committed to making a difference in the lives of local families.

For more information on Alliance Senior Care and their in-home care in Bloomfield Hills, MI, please visit their website at https://alliancesrcare.com.

About Alliance Senior Care:

Alliance Senior Care is a leading provider of in-home care services in Bloomfield Hills, MI. The company is known for its commitment to delivering compassionate and reliable support to seniors and their families. With a team of experienced caregivers dedicated to enhancing the lives of their clients, Alliance Senior Care offers a full spectrum of services to foster independence, comfort, and peace of mind for families and their loved ones.

Media Contact
Company Name: Alliance Senior Care
Contact Person: Dina Hurnevich
Email: Send Email
Phone: +1 248 274 2170
Address:7 W Square Lake Rd
City: Bloomfield Hills
State: MI
Country: United States
Website: allianceSRcare.com

Multi Patent Blockchain-Based Software with Potential to Unlock Massive Value from $100 Trillion Annual Equity Trading Market: BlackStar Enterprises Group, Inc. (Stock Symbol: BEGI)

$BEGI will unlock Blockchains full potential in the Financial Markets via their High Value Patents.

• Developer of Patented Blockchain-Based Software for Third-Party Companies.

• Goal to Facilitate Trading of all Registered Public Companies on the Blockchain as Cash Spot Markets Without Shorting.

• BEGI Technology Invites the Industry, Exchanges, and Dealers to Trade U.S. Registered Common Stock on the Blockchain.

• BEGI Intellectual Property Portfolio Covers All Regulated, Registered Equities and all Forms of Securities Traded on the Blockchain Through Broker-Dealers.

• AI advisors Estimates Blockchain Patent Assets could generate $50 million to $1 Billion in revenues.

• BEGI’s Intent to Generate Revenue Through Licensing, Subscription, Installation and Software Maintenance Fees.

• Ability to Streamline a public companies quarterly & annual audits on chain. BEGI’s Corporate Governance Blockchain platform could save billions annually in Administrative Costs and codify all corporate content every 90 days, demonstrating transparency to Regulators that will oversee a CENTRALIZED Blockchain.

• Global Equity Trading Market Exceeds $100 Trillion in Annual Trading Volume. Capturing Even a Fraction via Blockchain Solutions Could Deliver Major Revenue.

Blackstar Enterprise Group, Inc. (OTC Pink: BEGI) is comprised of its’” Core Blockchain Platform – B.D.T.P.™ and two (2) wholly owned subsidiaries that will support the BEGI core blockchain platform as follows:

1. BEGI Blackstar Digital Trading Platform™(“B.D.T.P.™”) The “Core Blockchain Platform.” Blackstar’s intent is to generate revenue through licensing, subscription, installation, and software maintenance fees of our patented blockchain-based software to third-party private and public companies through Blockchain Equity Trading™ (B.E.T.™) subscription services.

2. BEGI Blockchain Equity Management Corp. (“BEMC”): A Colorado Corporation intended to provide additional revenue streams by offering advisory and technology services in support of B.D.T.P.™ implementations and ongoing B.D.T.P.™ blockchain software maintenance.

3. BEGI Blockchain Equity SRO, Inc: A self-regulatory organization (SRO), a non-profit membership-based organization for the digital securities industry. The SRO will be populated with representatives from public companies, security attorneys, and other professionals to establish guidelines that advance the industry and enable investors to participate in blockchain-based markets with confidence and integrity.

BEGI Blockchain Intellectual Property: Patents Approved and Patents Pending

Currently, BEGI has six approved patents and one published pending non-provisional patent applications. BLACKSTAR’s patent portfolio, according to AI, could generate $50 million to 1 billion in revenues with participation in the $100 trillion annual U.S. Equity Market.

A BEGI patent enabling equity trading platform, equity funding platform, and the corporate governance on a blockchain could be extremely valuable, particularly as the market shifts towards trading regulated registered digital public companies on chain. Blackstar offers regulators centralized-decentralized finance (CeFI)-(DeFI). This hybrid system can be monitored by a Central Authority, IE. SEC, FINRA, Broker Dealers, Clearing and Transfer Firms. Its valuation would depend on factors like scope, exclusivity, and market potential as follows: 1. BEGI Market Opportunity Equity Trading Market: The global equity trading market exceeds $100 trillion in annual trading volume. Capturing even a fraction of this through blockchain solutions could yield significant revenue. Corporate Governance: The ability to streamline a public company’s quarterly & annual audits on chain. BEGI’s Corporate Governance Blockchain platform could save billions annually in Administrative Costs and codify all corporate content every 90 days, demonstrating transparency to Regulators, giving them the ability to regulate a CENTRALIZED Blockchain as a central authority.

Blockchain could revolutionize boardroom operations and save billions annually in administrative costs. Blackstar system trades registered assets that are securities on the block. Shares at Brokerage Firms in book-entry are fungible digital assets, and when directed with double encryption to a Blockchain Engine, only the customer sees the order. The Broker sees the confirmation and directs it to normal clearing and settlement. Tokenization is not needed to trade fungible securities digitally. 2. BEGI Patent Scope Unique Claims: If the patent covers a novel mechanism for integrating trading, funding, and governance on a blockchain, it could be foundational to the industry.

Potential Use Cases for BEGI Institutional Use: Stock exchanges, including Nasdaq, OTC), and EXCHANGE TRADED FUNDS. The clearinghouses might leverage the technology for real-time settlement in the future. BlackStar’s system plugs into the current registered broker-dealers back-office operation without changing rules or regs.

Private Equity and Startups: Smaller companies could use blockchain-based governance and funding blockchain platforms to streamline operations, codify corporate activity, building confidence in attorneys and accountants’representation of their history. BEGI’s Blockchain IPO platform will facilitate funding activity for private and public companies. BlackStar’s digital trading platform on the block for registered public companies allows its shareholders and potential investors to a spot cash market with no shorting. Shareholders trade the spread like Market Makers. Shorting restrictions with cash only benefits the public companies and shareholder price. Arbitrage traders and hedge traders bring liquidity daily to quit markets.

Decentralized Finance (DeFi) vs. Centralized Finance (CeFi): BEGI IP is the gatekeeper to trading digital securities in the SEC broker-dealer ecosystem.

BEGI Competitive Edge Blackstar IP creates a “moat” by preventing competitors from deploying similar blockchain solutions, and its strategic value skyrockets. BEGI Sees The Future of Registered Digital Asset Trading

On November 25thBEGI CEO Joseph E. Kurczodyna stated in a company news announcement that he believes the priority of millions of investors is to trade digital assets on the blockchain. The BEGI goal is to facilitate the trading of all registered public companies on the blockchain as cash spot markets without shorting. BEGI technology invites the industry, exchanges, and dealers to trade U.S. registered common stock on the blockchain.

Mr. Kurczodyna of BEGI originally recognized the potential of digital assets with the rise of Bitcoin in 2017, after spending three decades as a foreign currency and U.S. dollar trader. Mr. Kurczodyna realized that Bitcoin could be a world currency and shift the balance of global economic powers, including the theoretical ability to reduce deficit spending and manage the books of the largest economies using a Bitcoin hedge. From there, Mr. Kurczodyna came to believe that “with only one decentralized world currency in Bitcoin, that digital companies, man-made coins, tokens, or blockchain applications traded as coins may have other monetary motives.” Regarding Exchange-Traded Funds (ETFs), Mr. Kurczodyna thinks that “these types of funds helped open the investment world to trading Bitcoin as a security. Digital assets secured by exchanged traded funds send a clear signal to the investment banking world that digital assets that are registered as securities on the blockchain will trade through brokers as spot market ETFs.”

BEGI CEO, Mr. Kurczodyna is also of the opinion that “most unregistered, unaudited digital companies are trading imitations hooked to the Bitcoin movement. Many of these companies or applications may disappear like the end of a chain letter. Commonsense regulation tells us that the rules and regulations created in the 1930s provide guidance for unregistered securities. Registration and vetting by the SEC with an audit protects the investing public.”

Mr. Kurczodyna stated that “The BEGI blockchain technology can facilitate the trading of U.S. registered public companies on the blockchain through the broker-dealer ecosystem. BEGI technology trades common shares without creating a new digital security: common shares in book entry are fungible with their digital form.”

The BEGI intellectual property portfolio covers all regulated, registered equities and all forms of securities traded on the blockchain through broker-dealers.

For more information on $BEGI, visit: blackstareg.com

Disclaimer and Disclosure: www.aibrandnetwork.com

Media Contact
Company Name: BlackStar Enterprise Group, Inc.
Contact Person: Bryan P Hemphill, Media Relations
Email: Send Email
Phone: 559-359-1480
Address:4450 Arapahoe Avenue Suite 100
City: Boulder
State: Colorado
Country: United States
Website: blackstareg.com

Parkinson’s Disease Psychosis Treatment Market 2034: Clinical Trials, Medication, Pipeline Therapies, EMA, PDMA, FDA Approvals and Companies by DelveInsight

“Parkinson’s Disease Psychosis Market”

Parkinson’s Disease Psychosis companies market are Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences, and others.

(Albany, USA) DelveInsight’s “Parkinson’s Disease Psychosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Parkinson’s Disease Psychosis, historical and forecasted epidemiology as well as the Parkinson’s Disease Psychosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Parkinson’s Disease Psychosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Parkinson’s Disease Psychosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Parkinson’s Disease Psychosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Parkinson’s Disease Psychosis market.

Request for a Free Sample Report @ Parkinson’s Disease Psychosis Market Forecast

Some facts of the Parkinson’s Disease Psychosis Market Report are:

According to DelveInsight, Parkinson’s Disease Psychosis market size is expected to grow at a decent CAGR by 2034.
The Parkinson’s Disease Psychosis market size of in the 7MM was approximately USD 665 million in 2023.
Parkinson’s Disease Psychosis companies working in the treatment market are Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences, and others are developing therapies for the Parkinson’s Disease Psychosis treatment
Emerging Parkinson’s Disease Psychosis therapies in the different phases of clinical trials are- Iloperidone, Istradefylline, SAGE-718, ATH-1017, NYX-458, pimavanserin tartrate, AGB101, and others are expected to have a significant impact on the Parkinson’s Disease Psychosis market in the coming years.
In October 2024, Adaptive Research, an organization focused on broadening access to clinical trials, has announced its involvement in an innovative decentralized Parkinson’s disease study sponsored by PhotoPharmics Inc. The California Movement Disorders Center, a member of Adaptive Research’s network, will act as a site for the LIGHT-PD trial, which evaluates the effectiveness of Celeste® Specialized Phototherapy in managing Parkinson’s symptoms.
In September 2024, AbbVie’s newly acquired Parkinson’s disease treatment candidate, tavapadon, demonstrated a significant reduction in disease burden during a Phase III trial. The TEMPO-1 Phase III study (NCT04201093) assessed tavapadon at daily doses of 5mg and 15mg. The trial achieved its primary endpoint, with both dosing groups showing superior improvements compared to placebo at week 26, based on a combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).

Parkinson’s Disease Psychosis Overview

Parkinson’s Disease Psychosis (PDP) is a non-motor complication of Parkinson’s disease (PD), characterized by hallucinations, delusions, or other psychotic symptoms. It typically emerges in the later stages of Parkinson’s Disease, significantly impacting the patient’s quality of life and placing a burden on caregivers.

The exact cause of Parkinson’s Disease Psychosis is multifactorial, involving the progression of Parkinson’s pathology, imbalances in neurotransmitters like dopamine and serotonin, and side effects of dopaminergic therapies used to manage motor symptoms. Risk factors include advanced age, cognitive impairment, and prolonged use of Parkinson’s Disease medications.

Symptoms of Parkinson’s Disease Psychosis vary. Hallucinations, often visual, are the most common and may involve seeing people, animals, or objects that are not present. Delusions, such as false beliefs of infidelity or paranoia, can also occur. In some cases, patients are aware of these experiences (retaining insight), while others lose this awareness over time.

Treatment focuses on reducing distress and maintaining motor symptom control. Adjusting Parkinson’s Disease medications, adding atypical antipsychotics like pimavanserin (FDA-approved for Parkinson’s Disease Psychosis), or using clozapine at low doses can help manage symptoms. Non-pharmacological strategies, such as creating a calm environment and educating caregivers, are also essential. Early diagnosis and intervention improve outcomes and reduce the risk of complications such as caregiver burnout or institutionalization.

Do you know what will be the Parkinson’s Disease Psychosis market share in 7MM by 2034 @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market

Parkinson’s Disease Psychosis Market

The Parkinson’s Disease Psychosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Parkinson’s Disease Psychosis market trends by analyzing the impact of current Parkinson’s Disease Psychosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Parkinson’s Disease Psychosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Parkinson’s Disease Psychosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Parkinson’s Disease Psychosis market in 7MM is expected to witness a major change in the study period 2020-2034.

Parkinson’s Disease Psychosis Epidemiology

The Parkinson’s Disease Psychosis epidemiology section provides insights into the historical and current Parkinson’s Disease Psychosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Parkinson’s Disease Psychosis market report also provides the diagnosed patient pool, trends, and assumptions.

Interested to know how the emerging diagnostic approaches will be contributing in increased Parkinson’s Disease Psychosis diagnosed prevalence pool? Download report @ Parkinson’s Disease Psychosis Prevalence

Parkinson’s Disease Psychosis Drugs Uptake

This section focuses on the uptake rate of the potential Parkinson’s Disease Psychosis drugs recently launched in the Parkinson’s Disease Psychosis market or expected to be launched in 2020-2034. The analysis covers the Parkinson’s Disease Psychosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Parkinson’s Disease Psychosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Parkinson’s Disease Psychosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Parkinson’s Disease Psychosis Pipeline Development Activities

The Parkinson’s Disease Psychosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Parkinson’s Disease Psychosis key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Parkinson’s Disease Psychosis market share by 2034? Click here @ Parkinson’s Disease Psychosis Drugs Market

Parkinson’s Disease Psychosis Therapeutics Assessment

Major key companies are working proactively in the Parkinson’s Disease Psychosis Therapeutics market to develop novel therapies which will drive the Parkinson’s Disease Psychosis treatment markets in the upcoming years are Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences, and others.

Do you know how new drug’s market launch will be impacting the Parkinson’s Disease Psychosis market CAGR? Download sample report @ Parkinson’s Disease Psychosis Treatment Market

Parkinson’s Disease Psychosis Report Key Insights

1. Parkinson’s Disease Psychosis Patient Population

2. Parkinson’s Disease Psychosis Market Size and Trends

3. Key Cross Competition in the Parkinson’s Disease Psychosis Market

4. Parkinson’s Disease Psychosis Market Dynamics (Key Drivers and Barriers)

5. Parkinson’s Disease Psychosis Market Opportunities

6. Parkinson’s Disease Psychosis Therapeutic Approaches

7. Parkinson’s Disease Psychosis Pipeline Analysis

8. Parkinson’s Disease Psychosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Parkinson’s Disease Psychosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Parkinson’s Disease Psychosis Competitive Intelligence Analysis

4. Parkinson’s Disease Psychosis Market Overview at a Glance

5. Parkinson’s Disease Psychosis Disease Background and Overview

6. Parkinson’s Disease Psychosis Patient Journey

7. Parkinson’s Disease Psychosis Epidemiology and Patient Population

8. Parkinson’s Disease Psychosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Parkinson’s Disease Psychosis Unmet Needs

10. Key Endpoints of Parkinson’s Disease Psychosis Treatment

11. Parkinson’s Disease Psychosis Marketed Products

12. Parkinson’s Disease Psychosis Emerging Therapies

13. Parkinson’s Disease Psychosis Seven Major Market Analysis

14. Attribute Analysis

15. Parkinson’s Disease Psychosis Market Outlook (7 major markets)

16. Parkinson’s Disease Psychosis Access and Reimbursement Overview

17. KOL Views on the Parkinson’s Disease Psychosis Market

18. Parkinson’s Disease Psychosis Market Drivers

19. Parkinson’s Disease Psychosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s Disease Psychosis Treatment Market 2034: Clinical Trials, Medication, Pipeline Therapies, EMA, PDMA, FDA Approvals and Companies by DelveInsight